We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

54 hedge funds and large institutions have $180M invested in Prelude Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

5% less capital invested

Capital invested by funds: $188M → $180M (-$8.61M)

10% less funds holding

Funds holding: 60 → 54 (-6)

19.82% less ownership

Funds ownership: 85.54% → 65.72% (-20%)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

Holders
54
Holders Change
-6
Holders Change %
-10%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
15
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$4.26M
2
Millennium Management
Millennium Management
New York
+$529K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$516K
4
Morgan Stanley
Morgan Stanley
New York
+$315K
5
Jane Street
Jane Street
New York
+$291K

Top Sellers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
-$1.09M
2
Bank of America
Bank of America
North Carolina
-$791K
3
NYLIM
New York Life Investment Management
New York
-$495K
4
Barclays
Barclays
United Kingdom
-$491K
5
CANY
Caxton Associates (New York)
New York
-$395K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$2.85K – – –
Wells Fargo
52
Wells Fargo
California
$1.01K -$1K -164 -48%
Bessemer Group
53
Bessemer Group
New Jersey
$1K – – –
Daiwa Securities Group
54
Daiwa Securities Group
Japan
$1K – – –
HWM
55
HighMark Wealth Management
Minnesota
$285 – – –
CS
56
Candriam SCA
Luxembourg
– -$1.09M -179,850 Closed
NYLIM
57
New York Life Investment Management
New York
– -$495K -82,000 Closed
CANY
58
Caxton Associates (New York)
New York
– -$395K -65,453 Closed
Bank of New York Mellon
59
Bank of New York Mellon
New York
– -$174K -28,879 Closed
BFG
60
Bleakley Financial Group
New Jersey
– -$135K -22,325 Closed
Citadel Advisors
61
Citadel Advisors
Florida
– -$110K -18,232 Closed
MFS
62
Mirabella Financial Services
United Kingdom
– -$97K -16,058 Closed
Commonwealth Equity Services
63
Commonwealth Equity Services
Massachusetts
– -$92K -15,307 Closed
DFCM
64
Dark Forest Capital Management
Puerto Rico
– -$18.7K -3,092 Closed
Rockefeller Capital Management
65
Rockefeller Capital Management
New York
– -$15K -2,512 Closed
QT
66
Quantbot Technologies
New York
– -$4.83K -800 Closed
FIA
67
FNY Investment Advisers
New York
– -$1K -200 Closed
Federated Hermes
68
Federated Hermes
Pennsylvania
– -$393 -65 Closed
1 2
3

PRLD Hedge Fund Activity: Q1 2023 in Review

54 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2023, worth a combined $180M — down 4.6% from $188M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PRLD and 8 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Boxer Capital, opening a new position worth an estimated $4.26M. The largest seller was Candriam SCA, exiting entirely with an estimated $1.09M sold.

  • 54 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2023, down from 60 in Q4 2022.
  • Funds reported $180M of Prelude Therapeutics stock for Q1 2023, down 4.6% quarter-over-quarter.
  • 8 funds opened new Prelude Therapeutics positions in Q1 2023 and 14 closed out, a net change of -6 holders.
  • The largest Prelude Therapeutics buyer in Q1 2023 was Boxer Capital, an estimated $4.26M added.
  • The largest Prelude Therapeutics seller in Q1 2023 was Candriam SCA, an estimated $1.09M sold.

Based on aggregated 13F filings for Q1 2023.